activity during the MID task and not related to the difference of BOLD activity during reward anticipation versus the control condition. Discussion: In contrast to our expectation and previous results in healthy volunteers, RG7203 worsened indices of reward functions which we hypothesize may be due to a further enhancement of D2 antagonistic activity. The results do not support the utility of a PDE10 inhibitor as adjunctive treatment for negative symptoms in patients with schizophrenia. Given the previous observation that RG7203 enhanced reward functions in healthy volunteers who were not treated with D2 antagonist, the results of our study point to potentially deleterious effects of D2 blockade on reward functions and by extension on negative symptoms of schizophrenia. They raise the question if the presence of D2 antagonistic treatment curtails the potential effects of any adjunctive treatment for negative symptoms. Background: Lumateperone (ITI-007) is a first-in-class investigational agent in development for the treatment of schizophrenia. Acting synergistically through serotonergic, dopaminergic and glutamatergic systems, lumateperone represents a new approach to the treatment of schizophrenia and other neuropsychiatric disorders. Lumateperone is a potent antagonist at 5-HT2A receptors and exhibits serotonin reuptake inhibition. Lumateperone also binds to dopamine D1 and D2 receptors acting as a mesolimbic/mesocortical dopamine phosphoprotein modulator (DPPM) with pre-synaptic partial agonism and post-synaptic antagonism at D2 receptors and as an indirect glutamatergic (GluN2B) phosphoprotein modulator with D1-dependent enhancement of both NMDA and AMPA currents via the mTOR protein pathway. Methods: Lumateperone was evaluated in 3 controlled clinical trials to evaluate efficacy in patients with acute schizophrenia. In Study ITI-007-005, 335 patients were randomized equally across 4 treatment arms: one of two doses of lumateperone, risperidone (active control) or placebo QAM for 4 weeks. In Study ITI-007-301, 450 patients were randomized equally across 3 treatment arms: one of two doses of lumateperone or placebo QAM for 4 weeks. In Study ITI-007-302, 696 patients were randomized equally across 4 treatment arms: one of two doses of lumateperone, risperidone (active control) or placebo QAM for 6 weeks. In all 3 studies, the primary endpoint was change from baseline on the Positive and Negative Syndrome Scale (PANSS) total score compared to placebo. Also, a 6-week open-label safety switching study was conducted. In this ITI-007-303 study 302 patients with stable schizophrenia were switched from standard-of-care (SOC) antipsychotics and treated for 6 weeks with lumateperone QPM outpatient and then switched back to SOC for 2 weeks. Results: Two of the 3 randomized studies were positive. In Studies ITI-007-005 and ITI-007-301, lumateperone (60 mg ITI-007, equivalent to 42 mg active base) met the primary endpoint with statistically significant superior efficacy over placebo at Day 28 as measured by the PANSS total score (Study ITI-007-005 p=0.017; Study ITI-007-301 p=0.022). In Study ITI-007-302, neither dose of lumateperone separated from placebo on the primary endpoint in the intent-to-treat population; a high placebo response was observed in this study. Across all 3 efficacy trials, lumateperone improved symptoms of schizophrenia with the same trajectory and same magnitude of improvement from baseline on the PANSS total score. Lumateperone was well-tolerated with a favorable safety profile in all studies. In the two studies with risperidone included as an active control, lumateperone
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S44. LUMATEPERONE (ITI

S45. MENTALIZATION BASED TREATMENT FOR NON-AFFECTIVE PSYCHOTIC DISORDER
Results: This will be the first presentation of our trial results. Discussion: The clinical implications of the results and limitations of the trial will be discussed. Theoretical considerations suggest that mentalization-based treatment could be an effective treatment for social dysfunction and impaired mentalizing in NAPD. If Mentalization-based treatment for psychotic disorders proves to be effective at improving social functioning and mentalizing, it may provide a valuable addition to treatment as usual. 
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